Last reviewed · How we verify
Recombinant choriogonadotropin alfa
Recombinant choriogonadotropin alfa (hCG) is a recombinant human chorionic gonadotropin that stimulates ovarian follicle development and triggers final oocyte maturation in assisted reproductive technology.
Recombinant choriogonadotropin alfa (hCG) is a recombinant human chorionic gonadotropin that stimulates ovarian follicle development and triggers final oocyte maturation in assisted reproductive technology. Used for Final oocyte maturation and ovulation induction in assisted reproductive technology (ART) cycles, Controlled ovarian hyperstimulation in infertility treatment.
At a glance
| Generic name | Recombinant choriogonadotropin alfa |
|---|---|
| Also known as | OVITRELLE®. |
| Sponsor | Instituto de Investigacion Sanitaria La Fe |
| Drug class | Gonadotropin; recombinant hormone |
| Target | Luteinizing hormone receptor (LH-R) |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Fertility |
| Phase | Phase 3 |
Mechanism of action
This recombinant glycoprotein hormone mimics endogenous hCG by binding to luteinizing hormone (LH) receptors on ovarian granulosa and theca cells. It induces the final maturation of oocytes and triggers ovulation approximately 34–36 hours after administration, making it essential for completing controlled ovarian hyperstimulation cycles in fertility treatment.
Approved indications
- Final oocyte maturation and ovulation induction in assisted reproductive technology (ART) cycles
- Controlled ovarian hyperstimulation in infertility treatment
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Headache
- Injection site reactions
- Abdominal pain/discomfort
- Nausea
Key clinical trials
- FET-LET-2x2: Clinical Pregnancy Rates After Frozen Embryo Transfer in Natural and Modified Natural Cycles (NA)
- Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation (PHASE2)
- Comparing IVF/ICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol With Elonva Without GnRH Antagonist to Follicular Phase Day 2 Stimulation Fixed Day 5 Antagonist Protocol
- Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment (NA)
- Serum FSH Monitoring for Identification of an Optimal Range During Ovarian Stimulation
- Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05693 (P05713)
- Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial 38833 (P05783)
- A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: